REFERENCES
- Dimopoulos MA, Kiamouris C, Molopoulos LA. Solitary plasmacytoma of bone and extramedullary plasmacytoma. Hematol Oncol Clin North Am 1999; 13: 1294–57.
- Blade J, Perales M, Rosinol L, et al. Thalidomide in multiple myeloma: Lack of response of soft-tissue plasmacytomas. Br J Haematol 2001; 113: 422–4.
- Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492–4.
- Kumar S, Fonseca R, Dispenzieri A, et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood 2003; 101: 1715–7.
- Wechalekar AD, Sutton D, Voralia M, et al. Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma. Blood 2001; 98: 162a, (abstr).
- Dune BGM. Low-dose thalidomide in myeloma: efficacy and biologic significance. Semin Oncol 2002; 29: 34–8.